Syringes containing the Pfizer-BioNTech COVID-19 vaccine sit in a tray in a vaccination room at St. Joseph Hospital in Orange, Calif., Thursday, Jan. 7, 2021. (AP Photo/Jae C. Hong)
By Lauran Neergaard
New research suggests that Pfizer’s COVID-19 vaccine can protect against a mutation found in two easier-to-spread variants of the coronavirus that erupted in Britain and South Africa.
Those variants are causing global concern. They carry multiple mutations but share one in common that's believed to be the reason they are more contagious. Called N501Y, it is a slight alteration on one spot of the spike protein that coats the virus.
Most of the vaccines being rolled out around the world train the body to recognize that spike protein and fight it. Pfizer teamed with researchers from the University of Texas Medical Branch in Galveston for laboratory tests to see if the mutation affected its vaccine's ability to do so.
They used blood samples from 20 people who received the vaccine, made by Pfizer and its German partner BioNTech, during a large study of the shots. Antibodies from those vaccine recipients successfully fended off the virus in lab dishes, according to the study posted late Thursday on an online site for researchers.
The study is preliminary and has not yet been reviewed by experts, a key step for medical research.
But “it was a very reassuring finding that at least this mutation, which was one of the ones people are most concerned about, does not seem to be a problem” for the vaccine, said Pfizer chief scientific officer Dr. Philip Dormitzer.
A similar vaccine by Moderna is being rolled out in the U.S. and Europe, and on Friday was cleared in Britain. Moderna is doing similar testing to tell if its shot also works against the variants, as are makers of other types of COVID-19 vaccines.
But Dr. Anthony Fauci, the top U.S. infectious disease expert, recently told The Associated Press that vaccines are designed to recognize multiple parts of the spike protein, making it unlikely a single mutation could be enough to block them. Still, testing is needed to be sure.
Viruses constantly undergo minor changes as they spread from person to person. Scientists have used these slight modifications to track how the coronavirus has moved around the globe since it was first detected in China about a year ago.
British scientists have said the variant found in the U.K. – which has become the dominant type in parts of England -- still seemed to be susceptible to vaccines. That mutant has now been found in the U.S. and numerous other countries.
But the variant first discovered in South Africa has an additional mutation that has scientists on edge, one named E484K.
The Pfizer study found that the vaccine appeared to work against 15 additional possible virus mutations, but E484K wasn’t among those tested. Dormitzer said it is next on the list.
If the virus eventually mutates enough that the vaccine needs adjusting – much like flu shots are adjusted most years – that tweaking the recipe wouldn’t be difficult for his company's shot and similar ones. Both the Pfizer-BioNTech and Moderna vaccines are made with a piece of the virus genetic code, simple to switch, although it’s not clear what kind of additional testing regulators would require to make such a change.
Dormitzer said this was only the beginning “of ongoing monitoring of virus changes to see if any of them might impact on vaccine coverage.”
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
After months of investigation, board members from U.S. big oil companies were slated to appear before a House oversight committee this week to discuss their respective roles in pushing for climate initiatives internally. However, all four board members from Exxon, Shell, Chevron, and BP said they couldn't attend due to scheduling conflicts. Climate experts are testifying in their place about how effective big oil's climate promises have been so far. Meanwhile, President Joe Biden's lead science adviser Eric Lander has resigned after an investigation found he violated workplace policy. What will this mean for Biden's climate agenda? Amy Harder, executive editor of Cipher, a publication by Breakthrough Energy, joins Cheddar Climate to discuss.
Although this week's weather is predicted to be less severe than the 2021 storm, Texans are preparing for the worst - stocking up on supplies and emptying shelves in grocery stores, once again. Some Texans still have not recovered from last year's tragedy, and are heading into the next few weeks with anxiety for what's to come. Leslie Beyer, CEO of the Houston-based energy workforce & technology council, joins Cheddar News to discuss if the Texas grid will fail again.
The American Red Cross has declared its first-ever "national blood crisis" in the United States. Since COVID hit the U.S. in March 2020, blood donations have declined by 10 percent. American Red Cross Medical Director, Dr. Baia Lasky joined Cheddar News to discuss the country facing the worst blood shortage in over a decade. Dr. Lasky noted that as much as 40 percent of Americans are eligible to donate blood but only about 4 percent do so. "This is going to be ongoing," she said. "This is not an acute shortage. We really do need the commitment of people to come out and donate and donate again." Appointments to donate can be made by using the Red Cross Donor App, at RedCrossBlood.org, or calling 1-800-RED CROSS (1-800-733-2767).
Eight months after the National Football League announced $1 million in research into cannabinoids, the NFL-NFLPA Joint Pain Management Committee has awarded the funding to two teams of medical researchers at the University of California San Diego and the University of Regina. The NFL says the studies will investigate the effects of cannabinoids on pain management and neuroprotection from concussion in elite football players, respectively. Cheddar correspondent Chloe Ailello spoke with Jeff Miller, the executive vice president of communications, public affairs, and policy for the NFL, about the studies, as well as the recent lawsuit filed against the NFL by former Miami Dolphins head coach Brian Flores. "Maybe we can learn things from other alternative pain approaches that are going to benefit our player population and then sports medicine as a whole," Miller said.
On this episode of Cheddar Innovates: CEO of HereAfter AI discusses how artificial intelligence can be used to preserve family history and stories, and allow you to 'talk' to loved ones that have passed; Creator of the board game 'Travel Explore Discover' explains how she came up with the idea for this informative and educational board game, and how she's using the proceeds to give back to her community; Cheddar gets a look at Curiosity Stream's 'The Humboldt Current.'
Immunologist Dr. Purvi Parikh of the Allergy & Asthma Network joined Cheddar News to break down long Covid, in which Covid symptoms remain up to two years after infection; a phenomenon that has so far mystified health experts.
Solid-state battery maker Factorial Energy recently raised $200 million in a Series D round led by Mercedes-Benz and Stellantis. Factorial says the funding will be used to accelerate commercial production and deployment of its solid-state battery technology, which the company says is safer, and offers up to 50% more driving range than current lithium-ion technology. Factorial also has joint development agreements (announced in late 2021) with Mercedes-Benz, Stellantis, and Hyundai, three of the top 10 global automotive manufacturers, to commercialize its batteries. Factorial CEO Siyu Huang joined Cheddar News' Closing Bell to discuss.
David Malott, founder and chief architect at AI PlanetWorks joins Cheddar News to discuss the release of its augmented reality NFTs for the metaverse called 'TERA.'
A 2021 report from UK Research and Innovation found that the shipping industry makes up at least 2.5 percent of the world's total CO2 emissions. It's a problem that energy solutions company, Leclanché, is trying to solve. Founded in 1909, the company has been developing and producing batteries for more than 100 years. Today, Leclanché's lithium-ion battery is used to electrify not just ships, but also railroad locomotives, trucks, and specialty vehicles. Cheddar News spoke with Pierre Blanc, chief technology and industrial officer of Leclanché, to discuss.
